1. Home
  2. TGLS vs REPL Comparison

TGLS vs REPL Comparison

Compare TGLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

N/A

Current Price

$46.64

Market Cap

1.6B

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$21.74

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TGLS
REPL
Founded
1984
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
TGLS
REPL
Price
$46.64
$21.74
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
★ $57.25
$23.33
AVG Volume (30 Days)
327.4K
★ 3.2M
Earning Date
11-05-2026
10-28-2026
Dividend Yield
★ 1.31%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.65
N/A
Revenue
★ $370,984,000.00
N/A
Revenue This Year
$14.97
N/A
Revenue Next Year
$12.20
$513.15
P/E Ratio
$27.78
★ N/A
Revenue Growth
★ 17.98
N/A
52 Week Low
$34.05
$1.50
52 Week High
$54.85
$23.64

Technical Indicators

Market Signals
Indicator
TGLS
REPL
Relative Strength Index (RSI) 66.47 70.94
Support Level $41.54 $7.19
Resistance Level $47.37 N/A
Average True Range (ATR) 2.06 1.67
MACD 0.66 0.42
Stochastic Oscillator 83.78 82.86

Price Performance

Historical Comparison
TGLS
REPL

About TGLS Tecnoglass Inc.

Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: